usdaed

Three contributors to CORP-DEPO, ever the mavericks, have identified these neglected gems: Merck (MRK), Novo Nordisk (NVO), and Pfizer (PFE). Their rationale, though tinged with the optimism of the desperate, warrants scrutiny.

Dear Diary, today we confront the existential crisis of our generation: Should one blindly follow Warren Buffett’s portfolio like a financial lemming, or channel his wisdom while maintaining critical agency? Let’s dissect three of Berkshire’s darlings while I attempt to resist the urge to sell all my holdings and invest in a gold-backed llama farm.

Two such balloons, in my estimation, are Nvidia (NVDA) and Costco (COST). One thrives in the digital ether; the other anchors itself in the tangible world of groceries and memberships. Both, I daresay, are less susceptible to the whims of the crowd and more attuned to the tides of necessity. Let us dissect these prospects with the precision of a man who once counted his losses in shillings, not regrets.

Plug Power’s business model is as simple as my dating profile: “We make hydrogen fuel cells and electrolyzers.” Translating from corporate jargon: they turn water into hydrogen, then turn hydrogen back into energy. The byproducts are heat and water. How very… circular.

On paper, this is clean energy. In practice, it’s like trying to sell a Tesla to a gas station owner who still thinks “EV” stands for “Everyone’s Vain.” The company’s niche markets-forklifts in warehouses, for example-are promising, but let’s not pretend this is about to power the next *Fast & Furious* movie.

Wall Street’s love affair with Plug’s “story” died faster than my gym membership after the holiday season. The stock’s post-IPO peak? A 1-for-10 reverse split away from oblivion. Now it’s a penny stock, which is Wall Street’s way of saying, “This is a bad idea, but we’ll let you try it anyway.”

Once, such visions belonged to the realm of Boccaccio, where fantasies flourished unburdened by the weight of reality. Yet here we are, in an age where governments and airlines, like fickle suitors, have pledged their favor to these airborne chariots. Thus, Joby’s valuation, a mere $12 billion, now gleams in the eyes of investors like a gilded apple. But let us not mistake the shimmer for substance.

In a symphony of capitalist fervor, this fintech phoenix soars, a startling ascent of 55% year to date as of September 18, and an astronomical 204% over the past triennium. These figures induce a heady intoxication, leading one to ponder: should one engage with Nu’s stock at this juncture? Herein lie three compelling reasons that may see rationality and desire collide in thrilling turmoil.